A few supportive care updates:
1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi.
Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode
Link: https://doi.org/10.1200/OP-25-00100
2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes
Link: https://doi.org/10.1016/S1470-2045(25)00231-1
-------- Â
11:12
--------
11:12
Linvoseltamab & sunvozertinib
Two new drug approvals to talk about (after I misplaced my notes!)
-------- Â
9:36
--------
9:36
Antiandrogen Withdrawal
Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?
-------- Â
9:53
--------
9:53
June 2025 Updates
A plethora of recent updates:
-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)
-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib
-Pirtobrutinib improves PFS in CLL
-Zanubrutinib has a new dosage form on the way
-Another mitomycin product approved with "reverse thermal properties"
-A new regimen for FL of tafasitamab/rituximab/lenalidomide
-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
New Zealand